Starpharma Holdings Limited (SPHRF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Starpharma Holdings Limited (SPHRF) Healthcare & Pipeline Overview

Starpharma Holdings Limited develops and commercializes dendrimer-based pharmaceutical products, including VivaGel for bacterial vaginosis and DEP drug delivery technology for oncology, positioning itself in the competitive biotechnology sector with a focus on innovative drug delivery systems and antiviral applications.

What Is the Investment Thesis for SPHRF?

Starpharma's investment thesis hinges on the successful development and commercialization of its dendrimer-based products, particularly the DEP drug delivery technology. Key value drivers include the progression of DEP candidates through clinical trials, regulatory approvals, and subsequent market uptake. The company's gross margin of 60.1% indicates strong potential profitability if sales volumes increase. Upcoming catalysts include the advancement of DEP docetaxel, DEP cabazitaxel, DEP gemcitabine, and DEP irinotecan through Phase 2 and Phase 1/2 clinical trials. However, the company's negative P/E ratio of -60.29 and negative profit margin of -22.7% highlight the risks associated with investing in a biotechnology company that is still in the development stage. Successful partnerships and out-licensing deals for its DEP technology could also drive significant value.

Based on FMP financials and quantitative analysis

SPHRF Key Highlights

Market capitalization of $210M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 60.1% indicates strong potential profitability for commercialized products.
• Negative P/E ratio of -60.29 suggests the company is currently not profitable, typical for development-stage biopharmaceutical firms.
• Beta of 0.57 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development.

Who Are SPHRF's Competitors?

SPHRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SPHRF's Key Strengths?

Proprietary dendrimer technology platform.

• Established product in VivaGel for bacterial vaginosis.
• Strong pipeline of DEP drug delivery candidates.
• Experienced management team.

What Are SPHRF's Weaknesses?

Negative profitability and reliance on external funding.

• High research and development costs.
• Regulatory risks associated with drug development.
• Competition from established pharmaceutical companies.

What Could Drive SPHRF Stock Higher?

Phase 2 clinical trial results for DEP docetaxel.

• Phase 2 clinical trial results for DEP cabazitaxel.
• Phase 1/2 clinical trial results for DEP gemcitabine.
• Phase 2 clinical trial results for DEP irinotecan.
• Potential for new partnerships and licensing agreements for DEP technology.

What Are the Key Risks for SPHRF?

Negative return on equity (-16.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for DEP candidates.
• Competition from other drug delivery technologies.
• Changes in regulatory requirements.
• Negative profitability and reliance on external funding.
• High research and development costs.

What Are the Growth Opportunities for SPHRF?

• Expansion of VivaGel Market: VivaGel, Starpharma's non-antibiotic therapy for bacterial vaginosis, has the potential for further market penetration and geographic expansion. The global market for bacterial vaginosis treatment is estimated to be substantial, driven by the high prevalence of the condition. Successful marketing and distribution efforts, along with potential label expansions, could significantly increase VivaGel sales. Timeline: Ongoing.
• Advancement of DEP Oncology Pipeline: Starpharma's DEP drug delivery technology is being applied to a range of oncology drugs, including docetaxel, cabazitaxel, gemcitabine, and irinotecan. Positive results from ongoing clinical trials could lead to regulatory approvals and commercialization, providing significant revenue streams. The market for cancer therapies is one of the largest in the pharmaceutical industry. Timeline: 2-5 years.
• Partnerships and Licensing Agreements: Starpharma's DEP technology can be licensed to other pharmaceutical companies for use with their proprietary drugs. Successful partnerships and licensing agreements could generate upfront payments, milestone payments, and royalties, providing non-dilutive funding for Starpharma's own development programs. Timeline: Ongoing.
• Development of DEP Radiotheranostics: Starpharma is developing DEP radiotheranostics for cancer treatment and diagnosis, combining targeted drug delivery with imaging capabilities. This innovative approach has the potential to improve the efficacy and safety of cancer treatment while also providing diagnostic information. Timeline: 3-7 years.
• Expansion into Non-Oncology Applications: While Starpharma's initial focus has been on oncology, the DEP technology can also be applied to other therapeutic areas, such as infectious diseases and inflammatory disorders. Expanding into non-oncology applications could broaden Starpharma's market opportunities and reduce its reliance on the cancer therapeutics market. Timeline: 3-5 years.

What Are SPHRF's Competitive Advantages?

• Proprietary dendrimer technology platform.
• Patent protection for VivaGel and DEP technology.
• Clinical data supporting the efficacy and safety of its products.
• Established partnerships with pharmaceutical companies.

What Does SPHRF Do?

Starpharma Holdings Limited, founded in 1996 and headquartered in Abbotsford, Australia, is a biopharmaceutical company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications globally. The company's core technology revolves around dendrimers, which are highly branched molecules used for drug delivery and other applications. Starpharma's lead product is VivaGel, a non-antibiotic therapy designed for the treatment and prevention of bacterial vaginosis (BV). VivaGel is available in several markets and represents a key revenue stream for the company. Beyond VivaGel, Starpharma is developing a range of products, including the VivaGel condom, an antiviral condom, and VIRALEZE, an antiviral nasal spray. A significant part of their pipeline is the DEP (Dendrimer Enhanced Product) drug delivery technology, which aims to improve the efficacy and reduce the toxicity of existing drugs. DEP candidates include DEP docetaxel, DEP cabazitaxel, DEP gemcitabine, and DEP irinotecan, all in various stages of clinical trials for cancer treatment. The company also has DEP radiotheranostics for cancer treatment and diagnosis, DEP Antibody Drug Conjugates, DEP HER-2 ADC, DEP non-oncology candidates, and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. Starpharma's strategy involves both developing its own products and partnering with other pharmaceutical companies to leverage its DEP technology.

What Products and Services Does SPHRF Offer?

• Researches and develops dendrimer-based pharmaceutical products.
• Commercializes VivaGel, a non-antibiotic therapy for bacterial vaginosis.
• Develops VivaGel condom, an antiviral condom.
• Develops VIRALEZE, an antiviral nasal spray.
• Utilizes DEP drug delivery technology to improve existing drugs.
• Conducts clinical trials for DEP docetaxel, DEP cabazitaxel, DEP gemcitabine, and DEP irinotecan for cancer treatment.
• Develops DEP radiotheranostics for cancer treatment and diagnosis.
• Creates DEP Antibody Drug Conjugates and DEP HER-2 ADC.

How Does SPHRF Make Money?

• Develops and commercializes its own pharmaceutical products, such as VivaGel.
• Out-licenses its DEP drug delivery technology to other pharmaceutical companies.
• Generates revenue from product sales, licensing fees, milestone payments, and royalties.

What Industry Does SPHRF Operate In?

Starpharma operates in the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products. The industry is driven by innovation in drug delivery technologies and the development of novel therapies for unmet medical needs. Starpharma's focus on dendrimer technology positions it within the advanced drug delivery segment, competing with companies developing liposomes, nanoparticles, and other targeted delivery systems.

Who Are SPHRF's Key Customers?

• Patients seeking treatment for bacterial vaginosis.
• Consumers interested in antiviral condoms and nasal sprays.
• Pharmaceutical companies licensing Starpharma's DEP technology.

Starpharma Holdings Limited Financial Trajectory

Starpharma Holdings Limited (SPHRF) reported $10.8M in revenue for Q4 2025, reflecting 216.3% growth compared to the prior quarter. The company recorded net income of $1.4M, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, SPHRF averaged $-0.01 in diluted EPS.

Company Profile

Starpharma Holdings Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Abbotsford, AU. The company is led by CEO Cheryl Maley. SPHRF has traded publicly since 2007.

How Starpharma Holdings Limited Is Valued

Starpharma Holdings Limited carries a market capitalization of $210M, placing it in the micro-cap category. Relative to its peer group, SPHRF's quantitative score of 54/100 is roughly in line with the peer average of 51/100.

Return on equity for Starpharma Holdings Limited stands at -16.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.

Starpharma Holdings Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 23.57 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project Starpharma Holdings Limited revenue of about $15.8M for fiscal 2026, with EPS near $-0.01.

SPHRF Financials

SPHRF Latest News

No recent news available for SPHRF.

SPHRF Analyst Consensus

SPHRF MoonshotScore

What Investors Ask About Starpharma Holdings Limited (SPHRF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources